EP3923903A1 - Kosmetische und/oder dermatologische zusammensetzung zur bekämpfung von dehnungsstreifen - Google Patents
Kosmetische und/oder dermatologische zusammensetzung zur bekämpfung von dehnungsstreifenInfo
- Publication number
- EP3923903A1 EP3923903A1 EP20705238.2A EP20705238A EP3923903A1 EP 3923903 A1 EP3923903 A1 EP 3923903A1 EP 20705238 A EP20705238 A EP 20705238A EP 3923903 A1 EP3923903 A1 EP 3923903A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- composition
- weight
- stretch marks
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 239000002537 cosmetic Substances 0.000 title claims abstract description 12
- 208000031439 Striae Distensae Diseases 0.000 title claims description 36
- 206010040925 Skin striae Diseases 0.000 title claims description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 30
- 240000000662 Anethum graveolens Species 0.000 claims abstract description 25
- 235000007227 Anethum graveolens Nutrition 0.000 claims abstract description 25
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 23
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 17
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 16
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 16
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 7
- 150000000996 L-ascorbic acids Chemical class 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 210000004207 dermis Anatomy 0.000 description 8
- -1 alkaline earth metal salts Chemical class 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 241000244269 Peucedanum Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- YZQGFCOUFDWVGL-RNHFCUEFSA-N (5r)-5-[(1s)-1,2-dihydroxyethyl]-5-ethyl-3,4-dihydroxyfuran-2-one Chemical compound OC[C@H](O)[C@@]1(CC)OC(=O)C(O)=C1O YZQGFCOUFDWVGL-RNHFCUEFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910001867 inorganic solvent Inorganic materials 0.000 description 2
- 239000003049 inorganic solvent Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LALVCWMSKLEQMK-UHFFFAOYSA-N 1-phenyl-3-(4-propan-2-ylphenyl)propane-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1C(=O)CC(=O)C1=CC=CC=C1 LALVCWMSKLEQMK-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ZSNLEVJATWJBLU-UHFFFAOYSA-N 2-tert-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(C(C)(C)C)(OC)C(=O)C1=CC=CC=C1 ZSNLEVJATWJBLU-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- 244000136475 Aleurites moluccana Species 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- 241000125205 Anethum Species 0.000 description 1
- 244000125300 Argania sideroxylon Species 0.000 description 1
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000005589 Calophyllum inophyllum Species 0.000 description 1
- 235000009590 Calophyllum inophyllum Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000976924 Inca Species 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000208467 Macadamia Species 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MVHKJLPAUPVQIR-UHFFFAOYSA-N benzoic acid;potassium Chemical compound [K].OC(=O)C1=CC=CC=C1 MVHKJLPAUPVQIR-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000010653 helichrysum oil Substances 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- VTQCKDJHYPCDHH-UHFFFAOYSA-N octan-4-yl 2-methoxy-3-phenylprop-2-enoate Chemical compound CCCCC(CCC)OC(=O)C(OC)=CC1=CC=CC=C1 VTQCKDJHYPCDHH-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940048845 polyglyceryl-3 diisostearate Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to a cosmetic and / or dermatological composition intended for preventing and / or treating the appearance of stretch marks on the skin.
- Stretch marks are cutaneous streaks which appear in particular following an exaggerated distension of the skin, for example during weight gain, pregnancy, and / or a hormonal change, for example during puberty, and concern especially women.
- Stretch marks can be localized on the front of the abdomen, on the breasts, thighs and hips.
- stretch marks can arise under the effect of too rapid and sudden stretching of the skin: it is therefore the dermal tissue that is damaged, the target cell of these attacks being the fibroblast.
- the first subject of the present invention is a composition
- cosmetic and / or dermatological, in particular for topical application comprising:
- the composition of the first object can be used, in particular in non-therapeutic use, for the prevention and / or treatment of stretch marks on the skin.
- a second subject of the present invention is a composition for its application as a medicament for the prevention and / or treatment of stretch marks on the skin, comprising:
- composition of the second object can be formulated for topical application.
- composition according to the invention advantageously makes it possible to prevent and / or treat the appearance of stretch marks on the skin, while guaranteeing non-irritant properties for the skin.
- the expression “prevention of stretch marks on the skin” is understood to mean an action making it possible to reduce, or even avoid, the formation of stretch marks in the context of a cosmetic and / or dermatological treatment, by application. of the composition, before and during an event known to cause the appearance of stretch marks.
- the expression “treatment of stretch marks on the skin” is understood to mean an action making it possible to regress, or even to absorb, in the context of a cosmetic and / and dermatological treatment, in a visible and measurable manner, stretch marks already formed
- composition used according to the invention can be applied topically to areas of the skin liable to form stretch marks, comprising stretch marks in the course of formation or even comprising stretch marks already formed. These areas are well known to those skilled in the art, and may correspond to the area of the stomach, hips, buttocks, thighs and / or breasts.
- Hyaluronic acid is a natural glycosaminoglycan-type disaccharide-based polymer comprising D-glucuronic acid and N-acetylglucosamine units linked by glucosidic linkage.
- It can be in free, hydrolyzed form, or else in the form of one of its salts, such as alkali metal and alkaline earth metal salts, for example sodium, potassium, calcium or magnesium hyaluronate.
- salts such as alkali metal and alkaline earth metal salts, for example sodium, potassium, calcium or magnesium hyaluronate.
- the hyaluronic acid usable in the invention is commercially available in various forms suitable according to the intended uses. It can be produced industrially in large quantities by extraction from animal tissues such as rooster ridges, or by bacterial fermentation, or else by biotechnological process from plant substances, for example wheat.
- Hyaluronic acid or a salt thereof, by weight
- molecular weight of at most 1000 kDa has the advantage of being able to cross the barrier of the stratum corneum and thus stimulate
- CD44 receptors responsible for the neosynthesis of hyaluronic acid in the dermis are CD44 receptors responsible for the neosynthesis of hyaluronic acid in the dermis.
- Hyaluronic acid or one of its salts, can have a weight
- Hyaluronic acid or one of its salts, can also have a molecular weight of at most 800 kDa, and preferably at most 500 kDa.
- hyaluronic acid can have a molecular weight ranging from 300 kDa to 500 kDa.
- the studies carried out by the Applicant have shown that the choice of a hyaluronic acid meeting this condition allows an action in the epidermis, leading to an improvement in keratinocyte function, without directly affecting the dermis.
- composition of the invention may comprise an effective amount of hyaluronic acid or one of its salts, the effective amount being that which is necessary to obtain the effects expected according to the invention.
- composition of the invention may comprise from 0.01% to 5% by weight of hyaluronic acid or one of its salts, and of
- hyaluronic acid or one of its salts preferably from 0.1% to 1% by weight of hyaluronic acid or one of its salts, relative to the total weight of the composition.
- Ascorbic acid (or vitamin C) is an organic acid
- L form i.e. L-ascorbic acid
- natural products such as lemons, oranges, etc.
- the ascorbic acid derivatives can be chosen from salts, such as in particular sodium ascorbate, magnesium or sodium ascorbylphosphate; esters, such as in particular acetic esters,
- propionic or palmitic sugars, such as in particular glycosylated ascorbic acid; and one of their mixtures.
- Ascorbic acid, or a derivative thereof is preferably in a stabilized form.
- ascorbic acid, or one of its derivatives is in a substantially non-oxidizable form, and in particular a form which can be transported by a lipid.
- stabilized ascorbic acid i.e. stable derivative of ascorbic acid
- composition of the invention may comprise an effective amount of ascorbic acid or one of its derivatives, the effective amount being that which is necessary to obtain the effects expected according to the invention.
- composition of the invention may comprise from 0.01% to 5% by weight of ascorbic acid or one of its derivatives, and of preferably 0.1% to 2% of ascorbic acid or a derivative thereof, relative to the total weight of the composition.
- a peucedanum graveolens extract is an extract from a plant of the genus Peucedanum graveolens, a plant also known as dill.
- the extract can be the plant as a whole, and / or one or more constituent elements of the plant such as a flower, a seed, a root, a rhizome, a stem, a fruit and / or a leaf.
- the plant and / or the constituent elements of the plant can be prepared by grinding or chemical extraction well known to those skilled in the art.
- graveolens can be an extract from the fruit of Peucedanum graveolens.
- Such compounds may also be isolated from the plant by using extraction procedures well known to those skilled in the art, for example using organic solvents such as lower alcohols, Ci-C 8 alkyl polyols -C -C 8 alkyl ketones, Ci-C 8, alkyl ethers Ci-C 8 alkyl esters of Ci-C 8 of acetic acid and chloroform, and / or by using inorganic solvents such as water, inorganic acids such as hydrochloric acid, and inorganic bases such as sodium hydroxide.
- the solvent for the extraction procedures is preferably an inorganic solvent, and particularly preferably water: the extract of Peucedanum graveolens can thus advantageously be an aqueous extract.
- a particularly suitable extract of Peucedanum graveolens can be a product commercially available from BASF Beauty Care Solutions, under the reference Lys'Lastine, this product comprising an extract of Peucedanum graveolens in an amount of 5% to 10% by weight per relative to the total weight of said product.
- composition of the invention may comprise an effective amount of extract of Peucedanum graveolens, the effective amount being that which is necessary to obtain the effects expected according to the invention.
- composition of the invention may comprise from 0.001% to 2% by weight of extract of Peucedanum graveolens, and of
- compositions in accordance with the present invention can be presented in the forms conventionally used for topical application, that is to say in the form of a gel, lotion, emulsion (in particular cream or milk), spot-on, serum (or essence), mask or ointment, containing the usual compatible and pharmaceutically acceptable excipients and carriers. They may also be in the form of patches, tulles or controlled-release dressings, or of wipes soaked in a composition according to the invention.
- topical administration forms are prepared by techniques well known to those skilled in the art, and for example, in the case of a cream, by dispersing a fatty phase in an aqueous phase to obtain an oil emulsion. in water, or vice versa to prepare a water-in-oil emulsion.
- composition according to the invention may comprise one or more usual excipients, suitable in particular for external topical administration, in particular dermatologically and / or cosmetologically acceptable excipients.
- excipients suitable for the formulation are well known to those skilled in the art, and can be chosen, for example, from one or more of the compounds i to xv listed below:
- antioxidant vitamins other than vitamin C or a derivative thereof, such as vitamin E, for example tocopherol acetate or tocotrienol; natural polyphenols;
- buffers such as citric acid or a salt thereof; sodium hydroxide;
- gelling agents and / or thickeners such as natural gums such as xanthan gum; synthetic polymers, for example
- polyacrylamides of the Carbopol type crosslinked acrylate polymers and cellulose derivatives; sodium acrylate copolymers;
- emulsifiers and co-emulsifiers such as arachidyl glucoside
- cetearyl glucoside behenyl alcohol; cetearyl alcohol; cetostearyl alcohol; cetyl alcohol, steareth-2; steareth-21; isostearyl isostearate;
- emollients and surfactants such as octyl dodecanol; isononyl isononanoate; capric / caprylic triglycerides; cetearyl octanoate; isopropyl myristate; cetearyl isononanoate; polyglyceryl 3-diisostearate; hydrogenated polyisobutene; cetyl palmitate; cetyl phosphate; vegetable oils such as macadamia oil; lecithin; glyceryl caprylate;
- silicones such as dimethicone, cyclomethicone
- humectants / moisturizers such as glycerin; butylene glycol; propylene glycol;
- preservatives such as phenoxyethanol, dehydroacetic acid; benzoic acid; potassium sorbate; sodium benzoate; methyl or ethyl parahydroxybenzoates; chlorophenesin;
- agents for protecting against ultraviolet rays such as hydrophilic or lipophilic UV-A and UV-B sunscreens, chosen from
- benzophenone or a benzophenone derivative such as 2-hydroxy-4-methoxy-benzophenone; an ester of cinnamic acid, and more particularly octyl methoxycinnamate and ethyl-2-hexyl methoxycinnamate, or alternatively a cyano-b, b-diphenylacrylate such as octo-crylene, 4-methylbenzylidene camphor , and dibenzoylmethane derivatives such as 4-isopropyl dibenzoylmethane, t-butyl-methoxy dibenzoylmethane, and 4-methoxy-dibenzoylmethane; or such as pigments forming a UV screen; xi. exfoliating powders; fruit powders; or powders
- mattifying agents such as methyl methacrylate copolymer; xii. neutralizing agents;
- composition according to the invention can also comprise one or more usual additional active agents, suitable in particular for a
- complementary active agents suitable for the formulation are well known to those skilled in the art, and can be, for example, anti-aging agents, soothing active ingredients, purifying active ingredients, moisturizing active ingredients, antimicrobial active ingredients, etc.
- a third subject of the present invention is a use of an extract of Peucedanum graveolens, and more particularly a non-therapeutic use of an extract of Peucedanum graveolens, for the prevention and / or treatment of stretch marks on the skin.
- said extract is used in topical application.
- the active compounds are collated in Table 1 below:
- the Lys'Lastine compound mainly comprises water and approximately 7.5% by weight of Peucedanum graveolens extract relative to the total weight of said compound.
- the assets are diluted directly in a culture medium as described below.
- a 2 mm diameter biopsy was taken from a red stretch mark from a 22-year-old man.
- the classic explantation technique is used for the extraction of fibroblasts.
- the explant is cultured in "Dulbecco's modified Eagle's medium” medium supplemented with 10% fetal calf serum (FCS), 40 mg / l of gentamicin and 2 mg / l of fungizone (DMEMc) at 37 ° C. , in a humid atmosphere and in the presence of 5% C0 2 .
- FCS fetal calf serum
- DMEMc fetal calf serum
- DMEMc fetal calf serum
- the culture medium is renewed twice a week. When the fibroblasts are in sufficient quantity, they are detached under the action of trypsin-EDTA, subcultured and amplified under the same culture conditions.
- the equivalent dermis develop in a culture dish which consists of eight rectangular tanks. In each of them plunge two flexible blades, the lower parts of which are made up of grids on which the equivalent dermis clings during its polymerization. The equivalent dermis develops between two blades to result in a shape
- the fibroblasts cultured in a monolayer and treated or not are trypsinized and then counted to bring the cell suspension to
- a medium for manufacturing equivalent dermis is prepared by mixing:
- the mixture is poured into the rectangular tanks of the GlasBox plus® . In a few minutes at 37 ° C, a gel is formed. The culture medium containing or not the active compounds is added and the isometric forces are measured for 24 hours.
- test groups are as follows:
- the amounts expressed in parentheses correspond to amounts by weight relative to the total weight of the culture medium.
- the AUC and the Max are not significantly modified in the presence of 0.1% by weight of HA relative to the Control (decrease of approximately 4%).
- the AUC and the Max are not significantly modified in the presence of 0.1% by weight of AA relative to the Control (decrease of approximately 1%).
- the AUC and the Max are not significantly modified in the presence of 0.1% by weight of PG relative to the Control (decrease of approximately 4.5%).
- the active compounds AA, AH or PG used alone have little or no effect on the contractile forces of red stretch mark fibroblasts.
- Mixture C also has very little effect on the development of contractile forces.
- Mixture I in accordance with the invention allows a very significant reduction in contractile forces and thus significantly limits or even prevents the rupture of stretch mark fibroblasts.
- Mixture I has significant anti-stretch mark properties.
- the amounts of the various constituents of the composition in Table 7 are expressed in% by weight relative to the total weight of the composition.
- Hyaluronic acid is a hyaluronic acid of 450 kDa, marketed by the company Soliance, under the reference Primalhyal 450;
- vitamin C is vitamin C stabilized in the form of ethyl-ascorbic acid, marketed by the company Safic-Alcan under the reference ET-VC
- thickener and 17.5% by weight of humectant, relative to the total weight of said compound.
- humectant emollient, thickener, emulsifier, preservative and buffer
- emulsifier emulsifier
- preservative emulsifier
- buffer emulsifier
- This gel can be easily applied in particular to the stomach, hips, buttocks, thighs and / or breasts.
- this gel can be applied two to three times a day, preferably every 8 hours, and for at least 8 weeks, until satisfactory results are obtained.
- the gel described above can be applied at least once or twice a day, for example in the morning and / or in the evening, for at least 12 weeks, and preferably for at least 24 weeks. .
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1901393A FR3092493A1 (fr) | 2019-02-12 | 2019-02-12 | Composition cosmétique et/ou dermatologique pour lutter contre les vergetures |
PCT/FR2020/050092 WO2020165514A1 (fr) | 2019-02-12 | 2020-01-23 | Composition cosmétique et/ou dermatologique pour lutter contre les vergetures |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3923903A1 true EP3923903A1 (de) | 2021-12-22 |
Family
ID=67999711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20705238.2A Pending EP3923903A1 (de) | 2019-02-12 | 2020-01-23 | Kosmetische und/oder dermatologische zusammensetzung zur bekämpfung von dehnungsstreifen |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3923903A1 (de) |
FR (1) | FR3092493A1 (de) |
WO (1) | WO2020165514A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113101245A (zh) * | 2021-04-02 | 2021-07-13 | 广东袋鼠妈妈生物科技有限公司 | 一种具有修复妊娠纹功效的组合物和护理产品 |
WO2023235544A1 (en) * | 2022-06-03 | 2023-12-07 | Colgate-Palmolive Company | Skin care compositions and methods of use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2784029B1 (fr) | 1998-10-05 | 2001-01-05 | Pharmascience Lab | Methode de prevention et/ou de traitement cosmetique des vergetures de la peau et utilisation en dermatologie |
WO2018065918A1 (en) * | 2016-10-04 | 2018-04-12 | Mary Kay Inc. | Methods and compositions for treating striae distensae |
CN108434080A (zh) * | 2018-06-05 | 2018-08-24 | 深圳市旷逸生物科技有限公司 | 一种含表皮干细胞提取物的妊娠纹修复膏 |
-
2019
- 2019-02-12 FR FR1901393A patent/FR3092493A1/fr active Pending
-
2020
- 2020-01-23 EP EP20705238.2A patent/EP3923903A1/de active Pending
- 2020-01-23 WO PCT/FR2020/050092 patent/WO2020165514A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020165514A1 (fr) | 2020-08-20 |
FR3092493A1 (fr) | 2020-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1064931B1 (de) | Kosmetisches Mittel enthaltend mindestens einen Hydroxystilben und Ascorbinsäure | |
EP2204162B1 (de) | Verwendung von Monosacchariden und Zusammensetzung | |
EP3116599B1 (de) | Kosmetische verwendung von swertia-marine | |
EP1001740B1 (de) | Verwendung von ginsenoside rb1 zur stimulierung der elastinsynthese | |
LU93280B1 (fr) | Composition cosmétique à base d'extraits d'Avena sativa, de Lens esculenta et de Tropaeolum majus | |
WO2019025725A1 (fr) | Utilisation d'un extrait de péricarpe de nephelium lappaceum pour hydrater la peau et/ou les muqueuses | |
EP2691074A1 (de) | Zusammensetzung auf der basis von camellia japonica und polygonum hydropiper zum schutz der haut | |
EP3923903A1 (de) | Kosmetische und/oder dermatologische zusammensetzung zur bekämpfung von dehnungsstreifen | |
FR2926220A1 (fr) | Utilisation cosmetique d'un extrait de la plante pancratium maritimum comme agent cosmetique antioxydant et/ou inhibiteur de la melanogenese | |
EP2868313B1 (de) | Verbindung von Vitamin C und Hyaluronsäure für die Behandlung von Hautalterungseffekten | |
EP3077061B1 (de) | Zusammensetzung zur reduktion der hautalterung umfassend retinalaldehyd und einen extrakt von leontopodium alpinum | |
EP3085418B1 (de) | Kosmetische zusammensetzungen, die oligomere der hyaluronsäure und dedifferenzierte, aus bougainvillea extrahierte pflanzliche zellen beinhalten, die ein safranextrakt einkapseln | |
WO2015118281A1 (fr) | Composition pour lutter contre la chute des cheveux | |
EP2811977B1 (de) | Verwendung eines apfelbaumblattextraktes in einer kosmetischen haut-straffungs zusammensetzung | |
EP1316301A1 (de) | Kosmetisches oder dermatologisches Mittel enthaltend einen Retinoiden und/oder einen Carotenoiden und Acexamsäure | |
FR3021539A1 (fr) | Composition cosmetique et/ou dermatologique comprenant un extrait vegetal et un activateur de genes | |
FR2818135A1 (fr) | Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide | |
FR2828400A1 (fr) | Composition cosmetique ou dermatologique comprenant une association entre de l'igf1 et/ou un compose mimetique de l'igf1, et au moins un retinoide et/ou au moins un derive de retinoide | |
FR3099701A1 (fr) | Nouvelle utilisation cosmétique d’une combinaison d’oenothéine-B et de quercétine-3-O-glucuronide | |
WO2021044013A1 (fr) | Utilisation d'une composition comprenant un extrait de tulipa gesneriana | |
WO2003013464A1 (fr) | Composition comprenant une association entre l'igf1 et l'acide ascorbique | |
WO2003013466A1 (fr) | Composition comprenant une association de l'igf1 et au moins un isoflavonoide | |
FR2885049A1 (fr) | Composition a base d'extraits de graines d'araucaria pour la protection de l'epiderme. | |
FR2968216A1 (fr) | Nouvel actif antivergetures et compositions en contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210902 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LABORATOIRES NOREVA-LED |